Correction: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies by Nannini, Carlotta et al.
Available online http://arthritis-research.com/content/11/2/408
Page 1 of 1
(page number not for citation purposes)
It has been brought to our attention that Figure 2b in our
recently published paper [1] contains an error. Specifically,
we inadvertently entered –6.4 rather than +6.4 for the
Nadaskevich paper [2] reported in Figure 2b. Recalculation
of the summary estimate for diffusing lung capacity of carbon
monoxide (DLCO) in this figure revealed a summary mean
difference of 3.74, with 95% confidence interval (0.09 to
7.40). This effect is now statistically significant, although the
overall conclusion of our meta-analysis, that cyclophos-
phamide treatment did not result in clinically significant
improvement of pulmonary function, is unchanged by this
recalculation, as the improvement remains less than the
predefined criterion of 10%. The corrected figure 2b is given
here as Figure 1.
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Figure 1
Forest plot of the overall meta-analysis result in the randomized clinical trials. Comparison of the diffusing capacity for carbon monoxide (DLCO) at
12 months for patients with scleroderma lung disease treated with cyclophosphamide versus a control group. See Table 2 [1] for study details.
RCT, randomized clinical trial; SE, standard error; CI, confidence interval; Chi2, chi-squared; df, degree of freedom; I2, I-squared; Z, Z value; Mean
difference, weighted mean difference; Random, random-effects.